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PSMA PET for primary lymph node staging
of intermediate and high-risk prostate
cancer: an expedited systematic review
Lars J. Petersen1,2* and Helle D. Zacho1,2
Abstract
Background: PSMA PET is a promising method for primary lymph node staging in prostate cancer. However,
recent systematic reviews have identified only a limited number of studies with histopathology as a reference test.
Methods: A systematic search was performed in PubMed and the Cochrane Library. An expedited systematic
review was performed where we identified diagnostic studies in prostate cancer where a preoperative PSMA PET
for primary lymph node staging was compared to histopathology. The trials must have diagnostic data on a patient
level.
Results: Eighteen eligible clinical trials included 969 patients. The median patient number per study was 32 (range 10 to
208). Five trials were prospective, and nine trials had a consecutive enrolment of patients. Sixteen studies used Ga-68-PSMA-
11; there was one study with Cu-64-PSMA and one study with F-18-DCDFPyL. Twelve studies used PET/CT, four trials used
PET/MR. Most trials included patients with intermediate and high-risk. Diagnostic accuracy varied notably among the
studies; sensitivity ranged from 23 to 100%, specificity 67–100%, positive predictive value 20–100%, and negative predictive
value 41–100%. Weighted sensitivity was 59%, weighted specificity was 93%. Four studies compared PSMA PET with
anatomical imaging (CT or MRI); in all cases, sensitivity and specificity were superior with PSMA PET. Three studies
compared PSMA PET with multi-parametric or diffusion-weighted MRI with mixed results.
Conclusions: PSMA PET showed promising diagnostic accuracy for primary lymph node staging with pathology as
reference. Recommendation for PSMA PET for high-risk patients in clinical guidelines should be supported by confirmatory,
prospective trials with patient-relevant outcomes.
Keywords: Prostate cancer, Prostate-specific membrane antigen, Positron emission tomography, Staging, Lymph node
metastasis, Diagnostic accuracy
Background
Most urological societies recommend aorto-abdominal
computed tomography (CT) or magnetic resonance im-
aging (MRI) for primary lymph node staging of patients
with intermediate and high-risk prostate cancer [1–3].
These recommendations have been consistent for many
years despite the modest positive and negative predictive
values of anatomical imaging for lymph node metastases
[4]. Positron emission tomography (PET) tracers like F-
18- or C-11-choline have not shown superior to anatom-
ical imaging methods [5].
Within the last couple of years, a high number of pub-
lications have indicated an excellent diagnostic perform-
ance of prostate-specific membrane antigen (PSMA)
PET/CT for prostate cancer, primarily in biochemical re-
currence [6–9]. Also, some reports have shown encour-
aging data with PSMA PET/CT for the detection of
lymph node metastases for primary staging. A notable
number of systematic reviews have been published on
this topic since 2018 [8–13]. These systematic reviews
comprise a limited number (five to eight) original re-
ports with primary staging with pathology as reference.
We are aware of many more studies with PSMA PET/
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CT for primary staging than previously reported. Thus,
the objective was to provide an overview of trials with
PSMA PET for staging of prostate cancer.
Methods
Aim
The aim was to provide an up-to-date overview of diag-
nostic test accuracy trials of preoperative PSMA PET for
primary lymph node staging on a patient level in pros-
tate cancer patients with a final pathology reference for
lymph node metastasis.
Study design
This expedited systematic review was mostly compliant
with the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) guidelines for
reporting of systematic review [14]. The term ‘expedited’
indicates that some aspects of systematic review meth-
odology were kept at a minimum, e.g., one person did
the entire eligibility screening, and assessment of bias
comprised assessment of study design and recruitment
only. Due to the sequential search of papers, a flow dia-
gram of papers was not feasible. The review synopsis for
this study was not published in a public database. No
synthesis of results (meta-analysis) was performed. The
expedited methodology was chosen since the publication
velocity of papers within this area is so fast, that a full
systematic review would be largely outdated at the time
of publication.
Literature search
A literature search was performed in PubMed, which
was searched from inception up to August 16, 2019. We
used the following search string: (lymph node metastasis
OR staging) AND (positron emission tomography OR
PET) AND (prostate specific membrane antigen OR
psma) AND (prostate malignancy OR prostatic carcin-
oma OR prostate cancer OR prostatic neoplasm). We
did several searches in PubMed since end-2018 with re-
petitive and overlapping updates. A final search per-
formed on August 16, 2019, provided 413 references
(see Additional file 1). In addition, The Cochrane Library
was searched from inception through July 2, 2019, using
the search word ‘prostate specific membrane antigen’ or
‘prostate-specific membrane antigen’ (all text search). A
total of 123 hits were identified, none of which were
relevant supplementary hits compared to the references
identified in PubMed. A final search on August 16 also
showed 123 references. The validity of the PubMed
search string was verified by the identification of all ref-
erences presented in the latest systematic reviews of
68Ga-PSMA PET/CT for primary staging with pathology
as the reference [8–11, 13]. All references were imported
into EndNote X8 (Clarivate Analytics, Philadelphia, US)
and were evaluated for inclusion in the review. We did
not perform additional literature searches (‘grey’ litera-
ture, review of reference lists of eligible papers, or con-
tact to authors).
Eligibility criteria
According to the PICOS concept (patient, intervention,
comparator, outcome, study type), the following eligibil-
ity criteria were used: 1) The trial must comprise pa-
tients diagnosed with prostate cancer; 2) the patients
underwent preoperative PSMA PET for primary lymph
node staging, and 3) the reference test was histopath-
ology. In addition, 4) the trial must report individual
data or summary diagnostic accuracy findings on a pa-
tient level; and 5) it should include a minimum of five
patients per study fulfilling all the criteria mentioned
above. Based on the criteria mentioned above, 6) the
study design was limited to diagnostic test accuracy
studies. All languages were accepted, and any.
PSMA ligands were eligible. Among papers with mixed
types of cancers or settings (e.g., primary and secondary
staging), data should be extractable in accordance with
the eligibility criteria mentioned above.
Sorting and data extraction
All papers were initially reviewed for eligibility by the
reading of title and abstract by a trained reader (LJP).
Apparently ineligible papers were excluded. Potentially
eligible papers were reviewed in full text by reading sup-
ported by electronic searches within the text for relevant
words and phrases, e.g., lymph node, lymph node metas-
tasis, sensitivity, and true positive, and false positive. For
papers finally included in the review, two readers (LJP
and HDZ) independently extracted the data. A consen-
sus decision was made in the cases of disagreement.
Each paper was reviewed for the reporting of diagnos-
tic performance versus pathology reference (e.g., sensi-
tivity, specificity, positive and negative predictive values)
on a patient level. If diagnostic accuracy data were re-
ported by the authors, these figures were used. If data
were not reported (or incompletely reported), diagnostic
accuracy was determined from 2 × 2 tables of true and
false positive and negative cases. Any data available for
comparative index tests were also extracted. Some pa-
pers reported findings with pathology as the reference in
a subset of the patients. In these cases, we restricted the
study population to the patients with a pathology refer-
ence. If the prostate cancer risk classification was not re-
ported separately for the subset of patients with a
pathology reference, the risk class for classified as ‘not
reported’. If the study population in a paper comprised
patients with primary and secondary lymph node dissec-
tion (LND), the mean (or median, if reported) number
lymph nodes removed from the entire population was
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reported if data was not available from patients with pri-
mary LND.
Assessment of bias
Information about patient enrollment (prospective ver-
sus retrospective) and selection of patients (consecutive
or non-consecutive enrolment) was extracted. The as-
sessment of trial methodology was based on the actual
reporting. Thus, a trial was classified as prospective only
if the word ‘prospective’ was mentioned, the terminology
was clear (e.g., “we enrolled”), or the trial was classified
as an interventional trial. Finally, consecutive recruit-
ment of patients was acknowledged only if the phrase
“consecutive” or “unselected” was used, or it was clear
that the trial included all patients or an unbiased selec-
tion of patients examined in a well-defined period, and
the eligibility criteria were specified.
Statistics
Weighted analysis of sensitivity and specificity was per-
formed using the reported diagnostic accuracy data cor-
rected for the number of patients in each trial. No
analytical statistics were used.
Results
Description of the included papers
The total search strategy comprised 512 references, 389
references from PubMed (Additional file 1) and 123 ref-
erences from The Cochrane Library. Due to the sequen-
tial and overlapping searches, a flow chart cannot be
made of the papers read by full text and the reasons for
exclusion. The main reason for exclusion of papers after
full text reading was the lack of a pathology reference of
lymph node metastasis (reporting of detection rates
only). One paper selectively reported diagnostic accuracy
data on a lesional level with pathology as the reference
but no data on the patient level [15].
Eighteen studies, originating from ten countries (based
on the country of the first author) and published from
2016 and onwards (PubMed availability), reported data
on a patient level (Table 1). Most trials came from
Germany (n = 4) and Australia (n = 3). Most papers used
Ga-68-PSMA-11 (PSMA HBED-CC). PET/CT was most
frequently used; a few studies used PET/MR (entirely or
predominantly). The majority of studies were retrospect-
ive in design. Half of the studies recruited consecutive
patients; there was only one prospective study with con-
secutive recruitment. Generally, all papers reported the
distribution of patients with intermediate and high-risk
or reported proportions of patients with specific T-
stages, PSA levels, or Gleason scores. Even though some
papers did not report risk classes among patients with
pathology as a reference, most of these papers entire or
preferable recruited intermediate and high-risk patients
[23, 32]. All papers but one performed LND with radical
prostatectomy; one study solely included patients who
had laparoscopic LND prior to curatively intended
radiotherapy [33].
Diagnostic accuracy for PSMA PET for lymph node
metastasis
Diagnostic accuracy for the detection of lymph node
metastasis on a patient basis showed wide variations
(Table 2). Sensitivity ranged from 23 to 100%, speci-
ficity 67–100%, positive predictive value 20–100%,
and negative predictive value 41–100%. However, 15
of 18 studies reported a sensitivity of 50% or greater.
Specificity was generally good, 90% or better in most
studies. A weighted analysis showed a sensitivity of
59% (specificity 93%) based on the reported diagnos-
tic accuracy data and the number of patients in the
respective trials. The disease prevalence varied not-
ably from 4 to 65%. There was some variation of the
positive and negative predictive values, but the ma-
jority of trials presented values of 80% or better for
both positive and negative predictive values.
Comparison of PSMA PET with other index tests
A subset of reports compared PSMA PET with other
index tests (Table 2). Four papers compared PSMA PET
with guideline-recommended anatomical imaging (CT
or MRI). In all four reports, PSMA PET numerically out-
performed cross-sectional anatomical imaging. A few
studies applied multi-parametric or diffusion-weighted
MRI for lymph node staging with heterogeneous find-
ings when compared to PSMA PET.
Discussion
Cross-sectional anatomical imaging has been recom-
mended for patients with unfavourable intermediate and
high-risk prostate cancer for primary lymph node sta-
ging across urological guidelines for years despite known
insufficient diagnostic accuracy for both CT and MRI
[4]. With a weighted sensitivity of 42%, a specificity of
82%, and a positive predictive value of 32%, CT is not
the ideal imaging method in this setting. Here we sum-
marised findings from 18 diagnostic test accuracy trials
with PSMA PET and a valid reference test and found a
weighted sensitivity of 59%, a specificity of 93%, and
positive and negative predictive values of 80% or higher
in the majority of the trials. These findings indicate that
PSMA PET should be considered for primary staging in
prostate cancer.
PSMA PET has shown encouraging diagnostic properties
in prostate cancer since the first clinical trial was published
with Ga-68-PSMA-11 in 2012 [34]. Since then, the use of
PSMA PET has been evaluated in numerous settings, in-
cluding primary staging and biochemical recurrence, as
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Table 1 Study demographics. Data are from patients undergoing staging for newly diagnosed disease in whom a pathology
reference was applied
Ref Author Year Country Tracer Scanner Study
design
Recruitment Patients,
numbers
Risk group distribution Mean number of LN
removed per patient
1 Budaus et al.
[16]
2016 Germany Ga-68-
PSMA-
11
PET/CT Retro Non-con 30 High (100%) 20
2 Herlemann
et al. [17]
2016 Germany Ga-68-
PSMA-
11
PET/CT Retro Con 20 Int (20%), High (80%) 14
3 Maurer et al.
[18]
2016 Germany Ga-68-
PSMA-
11
PET/MR (73%),
PET/CT (27%)
Retro Con 130 Int (32%), High (68%) 21a
4 Van
Leeuwen
et al. [19]
2017 Australia Ga-68-
PSMA-
11
PET/CT Pro Non-con 30 Int (10%), High (90%) 18
5 Uprimny
et al. [20]
2017 Austria Ga-68-
PSMA-
11
PET/CT Retro Non-con 49 NR NR
6 Gupta et al.
[21]
2017 India Ga-68-
PSMA-
11
PET/CT Retro Non-con 12 High (100%) 20
7 Obek et al.
[22]
2017 Turkey Ga-68-
PSMA-
11
PET/CT Retro Non-con 51 High (100%) 20
8 Zhang et al.
[23]
2017 China Ga-68-
PSMA-
11
PET/CT Retro Con 42 NR 15
9 Park et al.
[24]
2018 USA Ga-68-
PSMA-
11
PET/MR Pro Non-con 33 High (45%), Int (55%) 12
10 Van
Leeuwen
et al. [25]
2018 The
Netherlands
Ga-68-
PSMA-
11
PET/CT Retro Con 140 Int (21%), High (79%) NR
11 Gorin et al.
[26]
2018 USA F-18-
DCFPyL
PET/CT Pro Non-con 25 High (100%) 13
12 Cantiello
et al. [27]
2018 Italy Cu-64-
PSMA
PET/CT Pro Non-con 23 Int (83), High (17) 18
13 Thalgott
et al. [28]
2018 Germany Ga-68-
PSMA-
11
PET/MR Retro Con 73 High (100%) 26
14 Berger et al.
[29]
2018 Australia Ga-68-
PSMA-
11
PET/CT Retro Non-con 50 NR (pT3, 54%; Gleason
≥8; 32%)
12a
15 Gupta et al.
[30]
2018 India Ga-68-
PSMA-
11
PET/CT Retro Con 23 NR (83% High based
on PSA and T-stage)
20
16 Yaxley et al.
[31]
2019 Australia Ga-68-
PSMA-
11
PET/CT Retro Con 208 High (59%), Int (41%( 14
17 Yilmaz et al.
[32]
2019 Turkey Ga-68-
PSMA-
11
PET/CT Retro Con 10 NR NR
18 Petersen
et al. [33]
2019 Denmark Ga-68-
PSMA-
11
PET/MR (85%),
PET/CT (15%)
Pro Con 20 High (95%), Int (5%) 29
aMedian
Abbreviations. Con consecutive, Int intermediate, LN lymph node, Non-con non-consecutive, NR not reported, Pro prospective, Retro retrospective
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shown in recent systematic reviews [8–13]. However, these
recent systematic reviews only present a fraction of the
knowledge of PSMA PET for primary lymph node staging.
Even though our systematic literature search included all
PSMA ligands, 16 of 18 trials were with Ga-68-PSMA. The
clinical trial documentation with PSMA PET originated
from 2016 and onwards with most trials published in 2018
and later. It may be speculated that the tremendous work
with systematic reviews and meta-analysis, including dupli-
cate search and selection, searched across several databases
and the grey literature, detailed bias assessment, may impair
the ability to show up-to-date evidence. With rapidly evolv-
ing methods like PSMA PET, expedited systematic litera-
ture reviews may better provide a status of the current
knowledge. We certainly acknowledge the place for system-
atic reviews and meta-analyses in particular to synthesise
cumulative evidence in other areas of medicine.
The 18 trials showed clinical compelling diagnostic per-
formance in those patients where primary lymph node sta-
ging is indicated (high-risk and unfavourable intermediate-
risk categories), even though some variations in diagnostic
accuracy were observed across the trials. The reasons for
the wide variations may, among others, be related to re-
search design, technical aspects of the PET/CT scanner and
image reconstruction, reader experience, the surgical pro-
cedure, and handling of the pathology specimens. Most
studies were of modest size, which together with variations
in the proportion of LN metastatic patients (4 to 65%) may
influence precision of the diagnostic test characteristics.
Also, it has been documented that wide disease spectrum,
non-consecutive recruitment, open-label reading of tests,
and retrospective data collection were associated with
higher estimate of diagnostic accuracy [35]. In this review
[33, 36], the proportion of high-risk patients varied from 17
to 100%, approximately 50% of the trials stated consecutive
recruitment, and blinding of readers were seldom reported.
There were five prospective trials, but only one prospective,
interventional trial with consecutive enrollment [33]. That
study was fully compliant with The Standards for Reporting
of Diagnostic Accuracy (STARD) [37], performed accord-
ing to the Good Clinical Practice requirements, but unfor-
tunately performed with older PET/CT scanners. Reader
experience with PSMA PET should also be taken into con-
sideration [38]; reader experience was seldom mentioned in
the 18 trials. In addition to the extent of surgical resection,
details for pathology assessment, including criteria for a
pathology-positive lymph node, should be considered; such
details were infrequently reported.
The weighted sensitivity and specificity of PSMA PET
outperformed the reported diagnostic accuracy of CT
and MRI published in the latest meta-analysis [4]. Four
trials directly compared PSMA PET with cross-sectional
Table 2 Diagnostic performance on a patient basis for the detection of lymph node metastasis with pathology as reference. Data
accuracy data from any comparative index test(s) are shown in parenthesis
Ref Author LNM (%) Sens
(%)
Spec
(%)
PPV
(%)
NPV
(%)
Comparative index tests
1 Budaus et al. [16] 40 33 100 100 69 None
2 Herlemann et al. [17] NR 91 67 83 80 None
3 Maurer et al. [18] 32 66 (44) 99 (85) 96 (58) 86 (77) CT
4 Van Leeuwen et al. [19] 37 64 95 88 82 None
5 Uprimny et al. [20] 37 61 94 85 81 None
6 Gupta et al. [21] 58 100 (57) 80 (80) 88 (80) 100 (57) MRI
7 Obek et al., [22] 29 53 (25) 86 (76) 61.5 (NR) 81 (NR) MRI/CT
8 Zhang et al. [23] 36 93 (96) 96 (96) 93 (88) 96 (100) mpMRI
9 Park et al. [24] 9 100 87 43 100 None
10 Van Leeuwen et al. [25] 36 53 (14) 88 (99) 71 (81) 76 (67) DW-MRI
11 Gorin et al. [26] 28 71 89 71 89 None
12 Cantiello et al. [27] 35 88 100 100 94 None
13 Thalgott et al. [28]a 34 60 100 100 83 None
14 Berger et al. [29] 4 50 (NR) 92 (NR) 20 (NR) 98 (NR) mpMRI
15 Gupta et al. [30] 39 78 93 88 87 None
16 Yaxley et al. [31] 26 38 93 68 81 None
17 Yilmaz et al. [32] 20 100 (100) 100 (38) 100 (29) 100 (29) mpMRI
18 Petersen et al. [33]b 65 23–39 (8;37) 100 (100;83) 100 (100;80) 41–47 (37;42) CT/MRI; DW-MRI
aPatients with equivocal PSMA scans were consider negative for lymph node metastases. bSensitivity analysis were performed where intermediate findings are
calculated as either benign or malignant). Abbreviations. LNM lymph node metastasis
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imaging. In all trials, PSMA PET numerically outper-
formed CT and MRI. A few trials compared PSMA PET
with functional MRI; the findings were heterogeneous,
so no firm conclusion could be made.
The differences in diagnostic accuracy among ana-
tomical and functional imaging methods may mainly
reflect the criteria for classifying an index test as posi-
tive for malignancy. With CT and MRI, a size criteria
of 10 or 15 mm, with or without additional radiological
criteria, are generally applied for pathological lymph
nodes [4, 39]. PET criteria combine anatomical and
functional findings with quite consistent observer
agreement across reporting guidelines [40]. Equivocal
imaging findings on PSMA (e.g. PSMA-RADS-3) still
represent a challenge; however, most studies in this sys-
tematic review reported PSMA results on a dichotom-
ous scale. Handling of equivocal findings can notable
influence diagnostic accuracy [41]. Recent studies with
PSMA PET have revealed that most lymph node metas-
tases are in fact quite small. In our own recent trial,
false-negative metastases on PSMA PET/CT had a me-
dian diameter of 4 mm, with only 3 of 30 lymph nodes
being larger than 10 mm; 31% of the patients with
lymph node metastases had micrometastasis (< 0.2 mm)
only [33].
When we searched for eligible papers for this review,
it was striking that approximately 50% of the papers
published in this area reported detection rates only, not
correlative findings with pathology. At staging, it is pos-
sible to do pathological staging, at least on a patient
basis. In other settings, e.g. biochemical recurrence,
pathology may be difficult to obtain. Such results should
be carefully evaluated due to possible verification bias
[42, 43] [33, 37]. In order to move PSMA PET higher in
the hierarchy of clinical evidence, we not only need large
prospective diagnostic test accuracy trials [44], but we
also need trials showing improvement of patient benefit,
e.g. improved outcome of having a preoperative PSMA
PET rather than CT or MRI. There are indications that
such a benefit can be documented; in a recent study by
van Leeuwen et al. [25], the biochemical recurrence rate
after radical prostatectomy was 17% among patients who
had no signs of lymph node metastasis on the PSMA
PET/CT compared to 50% of those in whom PSMA
identified lymph node involvement. Once clinical benefit
with PSMA PET has been documented, strong recom-
mendations in clinical practice guidelines will follow.
Conclusion
The current level of evidence indicated interesting diagnos-
tic performance of PSMA PET/CT for primary lymph node
staging of high-risk prostate cancer patients though there
were some variations across the studies. PSMA PET/CT
showed superior diagnostic performance compared to
anatomical imaging for lymph node staging in studies
where comparative data were reported. Since studies have
shown PSMA PET/CT to outperform bone scans, with or
without SPECT/CT, for the detection of skeletal metastases
[45–48], PSMA PET/CT may turn out to be a one-stop
modality for staging in these patients.
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